Form 4: Leap Therapeutics Chief Medical Officer Settles Restricted Stock Units
SEC Form 4 Filing
Cynthia Sirard, Chief Medical Officer of Leap Therapeutics, settled 22,500 Restricted Stock Units (RSUs) on March 28, 2025, receiving an equivalent number of common stock shares.
Summary
- Cynthia Sirard, the Chief Medical Officer of Leap Therapeutics, settled 22,500 Restricted Stock Units (RSUs) on March 28, 2025.
- This resulted in the issuance of 22,500 shares of Leap Therapeutics' common stock to Ms. Sirard.
- The RSUs were initially granted on January 31, 2022, and fully vested on January 31, 2025.
- The settlement was deferred by the Compensation Committee until March 28, 2025, due to potential insider trading policy restrictions.
- The share numbers have been adjusted to reflect a 10-for-1 reverse stock split that occurred on June 20, 2023.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.
Stakeholder Impact
- The settlement of RSUs impacts the total number of outstanding shares, which could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| January 31, 2022 | Date the Restricted Stock Units (RSUs) were granted to Cynthia Sirard. |
| January 31, 2025 | Date the Restricted Stock Units (RSUs) fully vested. |
| March 28, 2025 | Date the Restricted Stock Units (RSUs) were settled, and common stock was issued. |
| June 20, 2023 | Date of the 10-for-1 reverse stock split. |
| 04/01/2025 | Date of the form filing. |
Keywords
LEAP Therapeutics, Cynthia Sirard, Restricted Stock Units, RSUs, Common Stock, Settlement, Insider Trading, Reverse Stock Split, Form 4, LPTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.